F9302
Factor X Activated (Xa) from bovine plasma
aqueous glycerol solution
Synonym(s):
Factor Xa
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
CAS Number:
UNSPSC Code:
12352204
NACRES:
NA.54
MDL number:
Product Name
Factor X Activated (Xa) from bovine plasma, aqueous glycerol solution
form
aqueous glycerol solution
specific activity
≥50 units/mg protein
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Quality Level
Gene Information
cow ... F10(280787)
Looking for similar products? Visit Product Comparison Guide
Application
Bovine Factor Xa is used for site specific cleavage of recombinant fusion proteins containing an accessible Factor Xa recognition site for removal of affinity tags.
Fusion proteins are commonly expressed with a factor Xa cleavable Ile-Glu (or Asp)-Gly-Arg-↓-X sequence. Typically 1 mg of fusion protein can be incubated with 10 μg of factor Xa for 2.5 hours at 37 °C.
Biochem/physiol Actions
Factor Xa catalyzes the hydrolysis of the Arg-Thr and then Arg-Ile bonds in prothrombin to yield active thrombin.
The fairly strict recognition sequence is Ile-Glu (or Asp)-Gly-Arg-↓-X.
It may sometimes cleave at other basic residues, depending on the conformation of the target protein. Factor Xa will not cleave if a proline residue follows the arginine of the recognition sequence.
pH Optimum: 7.6-8.0
Temperature Optimum: 37 °C
The fairly strict recognition sequence is Ile-Glu (or Asp)-Gly-Arg-↓-X.
It may sometimes cleave at other basic residues, depending on the conformation of the target protein. Factor Xa will not cleave if a proline residue follows the arginine of the recognition sequence.
pH Optimum: 7.6-8.0
Temperature Optimum: 37 °C
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
General description
Factor Xa is a serine endoproteinase and a member of the S1 peptidase family. Factor Xa plays a critical role in the coagulation cascade by catalyzing the proteolytic conversion of prothrombin to active thrombin. Factor Xa′s prothrombin conversion activity is greatly enhanced in vivo when complexed with factor V, calcium ions and phospholipids on the activated platelet surface.
The zymogen form, Factor X, is activated in vivo by two different pathways. The intrinsic pathway utilizes a catalytic complex composed of factor IXa, factor VIII, phospholipids and calcium ions. The extrinsic pathway utilizes a complex of factor VII and tissue factor. The factor X zymogen is a 55 KDa glycoprotein with a light and heavy chain joined by a single disulfide.
The zymogen form, Factor X, is activated in vivo by two different pathways. The intrinsic pathway utilizes a catalytic complex composed of factor IXa, factor VIII, phospholipids and calcium ions. The extrinsic pathway utilizes a complex of factor VII and tissue factor. The factor X zymogen is a 55 KDa glycoprotein with a light and heavy chain joined by a single disulfide.
Other Notes
One unit of activated Factor X will liberate 1.0 μmole of p-nitroanilide from N-benzoyl-L-isoleucyl-L-glutamyl-L-glycyl-L-arginine-p-nitroaniline per minute at pH 8.3 at 37 °C.
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
动植物源性产品
低风险生物材料
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Taki Galanis et al.
Hospital practice (1995), 41(1), 26-36 (2013-03-08)
Nonvalvular atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia occurring in patients in the United States. The primary clinical consequence of AF is an increase in the risk and severity of strokes. Treatment guidelines recommend anticoagulation therapy
[Xarelto: other advantages].
Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec, 10(1), 59-59 (2013-02-06)
Doron Bushi et al.
Journal of neuroscience research, 96(8), 1406-1411 (2018-05-16)
Factor Xa (FXa) plays a critical role in the coagulation cascade by generation of thrombin. During focal ischemia thrombin levels increase in the brain tissue and cause neural damage. This study examined the hypothesis that administration of the FXa inhibitor
Monitoring the anti-Xa anticoagulants, from heparin to eliquis.
George A Fritsma
Clinical laboratory science : journal of the American Society for Medical Technology, 26(1), 48-53 (2013-03-14)
Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
The Medical letter on drugs and therapeutics, 55(1409), 9-10 (2013-02-06)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service